The transaction has been unanimously approved by the board of directors of both companies and is expected to be completed by the end of 2019.
See Also: Mylan, Pfizer's Upjohn To Merge And Create New Company
Upon closing of the deal, Exact Sciences shareholders are expected to own approximately 91% of the combined company, and Genomic Health stockholders are expected to own approximately 9%. Genomic Health stockholders will receive $27.50 in cash and $44.50 in shares of Exact Sciences stock.
Exact Sciences shares are trading down 4.6% at $112.45 in Monday’s pre-market session. The stock has a 52-week high of $121.98 and a 52-week low of $47.78.
Genomic Health shares are trading higher by 1.9% at $70 per share.
See more from Benzinga
- Mylan, Pfizer's Upjohn To Merge And Create New Company
- Pfizer Reports Mixed Q2 Earnings, Lowers Guidance
- Mylan Reports Q2 Earnings Beat
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.